Early peripheral psoriatic arthritis: Baseline features of the first 186 patients in the French Nationwide APACHE Cohort.
Pascal Claudepierre, Cecile Gaujoux-Viala, Arnaud Constantin...
https://pubmed.ncbi.nlm.nih.gov/40441347Actively Recruiting
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-04-27
425
Participants Needed
3
Research Sites
261 weeks
Total Duration
Psoriatic arthritis (PsA) is a chronic inflammatory disease that can cause progressive and irreversible joint damage, often linked to personal or family history of psoriasis. This research aims to follow patients with recent peripheral arthritis attributed to PsA to describe the severity of joint damage over 5 and 10 years and identify factors like genetic, environmental, clinical, and treatment-related influences that predict this damage. The study will create a unique long-term database to better understand the disease and guide new treatment targets and assessments. This is a prospective national study involving 425 patients across 30 centers, followed for 10 years after experiencing their first episode of peripheral arthritis within the past year. Standardized visits will collect clinical information, patient-reported outcomes, lab tests, and samples including plasma, serum, urine, RNA, and DNA. Imaging assessments such as X-rays, ultrasounds, and MRI will be performed at different times. No treatment decisions will be made during these visits as it is an observational study. Participants will attend regular scheduled visits over the 10-year period where various clinical and laboratory data will be gathered. Researchers will monitor joint damage through X-rays at 5 and 10 years, assessing erosions, joint space narrowing, and periostitic lesions. The study will also collect patient-reported outcomes and biological samples to support multiple research projects. Participation requires informed consent and affiliation to a social security system, with safety and language ability monitored throughout.
CONDITIONS
APACHE Cohort (A Psoriatic Arthritis CoHort)
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants are followed for up to 10 years with standardized visits to collect clinical data, patient-reported outcomes, lab parameters, biological samples, and imaging assessments. This observational stage does not involve any therapeutic intervention.
Standardized visits throughout the 10 years follow-up
Total: 3 locations
1
Henri-Mondor Hospital
Créteil, France, 94000
Actively Recruiting
2
Lapeyronie Hospital
Montpellier, France, 34090
Actively Recruiting
3
Saint Joseph Hospital
Paris, France, 75014
Actively Recruiting
P
Pascal CLAUDEPIERRE, PHD
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Pascal Claudepierre, Cecile Gaujoux-Viala, Arnaud Constantin...
https://pubmed.ncbi.nlm.nih.gov/40441347